News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Deals
Actavis to Vie with Teva Pharmaceutical Industries Limited for Ratiopharm
February 17, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Iceland's Actavis will forgo backing from Swedish buyout firm EQT as it prepares to square off against larger peer Teva (TEVA.TA) in the bidding for generic drug maker Ratiopharm, several people familiar with the auction said.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
Pfizer
MORE ON THIS TOPIC
Earnings
Tariffs Keep Biogen Execs Busy in Q1 but Impacts Expected To Be Minimal
May 1, 2025
·
3 min read
·
Annalee Armstrong
Deals
Novartis Strikes on M&A, Leading a Line of Big Pharmas With Cash to Spend
April 30, 2025
·
5 min read
·
Annalee Armstrong
Mergers & acquisitions
Novartis Drops up to $1.7B to Bolster Oligo Pipeline With Regulus Buy
April 30, 2025
·
2 min read
·
Tristan Manalac
Earnings
GSK Optimistic About M&A Prospects Despite Trump Tariff Threats
April 30, 2025
·
2 min read
·
Tristan Manalac